Neuralstem Updates ALS Clinical Trial Progress: Approved To Dose Last Cohort Of Patients

Neuralstem Updates ALS Clinical Trial Progress: Approved To Dose Last Cohort Of Patients
Neuralstem, Inc. (NYSE Amex: CUR) updated the progress of its ongoing Phase I human clinical trial of the company’s spinal cord stem cells in the treatment of ALS (amyotrophic lateral sclerosis, or Lou Gehrig’s disease) at Emory University in Atlanta, Georgia. The company announced that, after reviewing the safety data from the first nine patients, the trial’s Safety Monitoring Board has …
Read more on Medical News Today

Study on non-surgical approach for treatment of liver hydatidosis
Concerning treatment, until recently the only definitive treatment for hydatid disease had been surgery. Different surgical techniques and procedures have been carried out and even in some cases, a liver transplant has been required. Advances in drug therapy has been influenced by the introduction of albendazole and accelerated by addition of praziquantel, but this requires a long period of …
Read more on News-Medical-Net

Idenix Plunges On Drug Program Update
BOSTON — Shares of Idenix Pharmaceuticals plunged 23% to $ 3.09 early Thursday, the morning after the biotech group issued updates on its hepatitis C and HIV drug development programs. Idenix said that due to liver toxicity concerns, it was discontinuing development of its hepatitis C drug candidate IDX320. It added that while US regulators still have a partial clinical halt order imposed on …
Read more on FOX Business